Tevimbra
Payments companies reported to CMS as associated with Tevimbra. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tevimbra, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tevimbra
These are the largest totals companies reported as associated with Tevimbra. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ronan Kelly | Dallas, TX | Medical Oncology | $112,047.41 |
| Michael Morse | Durham, NC | Hematology & Oncology | $76,657.12 |
| Amit Mahipal | Rochester, MN | Medical Oncology | $54,931.87 |
| Mohit Narang | Owing Mills, MD | Medical Oncology | $49,628.24 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $48,252.81 |
| Marcia Cruz Correa | San Juan, PR | Gastroenterology (Internal Medicine) | $44,224.19 |
| Farshid Dayyani | Orange, CA | Medical Oncology | $41,965.53 |
| Fadi Braiteh | Las Vegas, NV | Medical Oncology | $39,309.78 |
| Uqba Khan | Brooklyn, NY | Hematology & Oncology | $35,322.67 |
| Mohammed Al Hallak | Detroit, MI | Hematology & Oncology | $32,304.37 |
Prescribed Tevimbra?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.